| abstract |
The purpose of the present invention is to provide, inter alia: a detection agent for specifically detecting bladder cancer stem cells; a tumor antigen peptide that is specifically presented by bladder cancer stem cells; a drug composition that contains the aforementioned tumor antigen peptide as an active ingredient, and that is useful for preventing and/or treating treatment-resistant bladder cancer; and a method for screening such a tumor antigen peptide. Provided is a tumor antigen peptide, or a motif substitution product thereof, that has HLA connectivity and that is formed from 8-14 consecutive amino acids in the amino acid sequence of a protein coded by a gene selected from the group consisting of GRIK2 and Claspin. |